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Abstract
Although circulating levels of adrenomedullin (ADM), a newly reported vasodilatory peptide with 52 amino acid residues
in the human and 50 amino acid residues in the rat, are elevated during the early and late stages of sepsis, ADM levels in
cardiovascular tissues and its precise localization remain to be determined. To study this, rats were subjected to sepsis by
cecal ligation and puncture (CLP), followed by administration of 3 ml/100 g b.wt. normal saline to these and sham-operated
animals. The heart and thoracic aorta were harvested at 5 h (i.e. the early stage of sepsis) and 20 h (late sepsis) after CLP.
Tissue levels of ADM were determined by radioimmunoassay. The localization of ADM in the left ventricle and thoracic
aorta was examined by using immunohistochemistry and electron microscopy techniques. The results indicated that ADM
levels in the heart and thoracic aorta increased significantly at 5 h after CLP and remained elevated at 20 h after the onset of
sepsis. Immunohistochemistry findings showed that ADM immunoreaction products were localized in the cytoplasm of the
cardiac myocytes and aortic endothelial cells. Using electron microscopy, ADM immunoreaction products were found in the
cytoplasmic matrixes. The immunostainings were also associated with the outer membranes of mitochondria and vesicles of
the myocytes as well as vascular endothelial cells. It appears that the cardiovascular tissues, among other organ systems,
contribute to the increased levels of plasma ADM under those conditions. Since ADM is localized in different cell
populations in the heart and the large blood vessel (i.e. myocytes versus vascular endothelial cells), this peptide may play a
differential role in regulating cardiac and vascular functions during sepsis as an autocrine and/or paracrine
mediator. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Sepsis, septic shock, and the ensuing multiple or-
gan failure are the most common causes of death in
the surgical intensive care units. Despite advances in
the management of sepsis with various novel thera-
peutic agents and £uid resuscitation, the morbidity
and mortality from sepsis still remain high [1,2]. Pol-
ymicrobial sepsis is characterized by hyperdynamic
circulation at the early stage and hypodynamic cir-
culation at the late stage [3]. Determination of the
factors producing the hemodynamic and cardiovas-
cular changes during the course of sepsis appears to
be important for the understanding of the mecha-
nisms responsible for the transition from the early,
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hyperdynamic phase to the late, hypodynamic phase
of sepsis [4,5].
Adrenomedullin (ADM) is a newly reported vaso-
dilatory peptide with 52 amino acid residues in the
human and 50 amino acid residues in the rat [6,7].
Adrenomedullin has partial homology with calcito-
nin gene-related peptide (CGRP) [6]. Intravenous ad-
ministration of ADM has been shown to produce a
long-lasting hypotensive e¡ect in the rat [8]. Under
normal conditions, ADM exists in the circulation at
concentrations comparable to other vasoactive pep-
tides, such as angiotensin II and vasopressin [9]. It
has been reported that ADM mRNA is expressed in
a variety of tissues/cells, including the cultured vas-
cular smooth muscle cells, cultured endothelial cells,
heart, lung, kidneys, liver and intestines [10^12].
Since plasma levels of ADM increase following heart
failure [13^15], ADM may regulate cardiovascular
response under those conditions as a circulating hor-
mone [16]. Moreover, the expression of ADM in a
variety of cell populations would suggest that ADM
plays a role, not only as a circulating hormone, but
also as a local autocrine and/or paracrine mediator
[17].
Clinical reports have indicated that circulating
ADM increases signi¢cantly in the patient with septic
shock [16,18]. Plasma concentrations of ADM in
such patients were more than 40 times higher than
the concentration in normal subjects [18]. When he-
modynamic parameters were compared with plasma
ADM levels, a correlation was found between plas-
ma ADM concentrations and cardiac index, stroke
volume index, and heart rate [19]. Thus, the in-
creased plasma levels of ADM during sepsis appear
to be associated with the hyperdynamic state charac-
terized by high cardiac output and systemic vasodi-
lation [19]. Although our recent studies have indi-
cated that an increase in plasma ADM occurs at
the early as well as late stages of sepsis [4], it remains
unknown whether ADM levels in the cardiovascular
tissues increase under such conditions and, if so,
what is the precise localization of ADM in the heart
and aorta. To examine this, tissue levels of ADM
were measured and immunohistochemistry and elec-
tron microscopy techniques were employed to de-
termine the precise cellular localization of this pep-
tide.
2. Materials and methods
2.1. Animal model of polymicrobial sepsis
Polymicrobial sepsis was induced in male Sprague^
Dawley rats (275^325 g, Charles River, Wilmington,
MA) by cecal ligation and puncture (CLP) as de-
scribed previously [20]. Brie£y, rats were fasted over-
night before the induction of sepsis, but were allowed
water ad libitum. The animals were anesthetized with
methoxy£urane inhalation and a 2-cm ventral mid-
line incision was made. The cecum was then exposed,
ligated just distally to the ileocecal valve to avoid
intestinal obstruction, punctured twice with an 18-
gauge needle, and returned to the abdominal cavity.
The abdominal incision was then closed in layers and
the animals received 3 ml/100 g b.wt. normal saline
subcutaneously immediately after CLP. The area of
incision was bathed with 1% lidocaine to provide
analgesia throughout the study period. Sham-oper-
ated animals underwent the same surgical procedure
except that the cecum was neither ligated nor punc-
tured. The animals were then divided into four
groups (i.e. 5 and 20 h after CLP or sham-operation)
with ¢ve to six rats in each group. The heart and
thoracic aorta were harvested for tissue ADM assay
immediately following the death of the animals by an
overdose of sodium pentobarbital at 5 or 20 h after
CLP or sham operation. It should be noted that 5 h
after CLP represents the early, hyperdynamic stage
of sepsis and 20 h after CLP represents the late,
hypodynamic stage of sepsis [3]. The experiments de-
scribed here were performed in adherence to the Na-
tional Institutes of Health guidelines for the use of
experimental animals. This project was approved by
the Institutional Animal Care and Use Committee of
Rhode Island Hospital, Providence.
2.2. Tissue ADM determination
Tissue levels of ADM were measured by using a
radioimmunoassay (RIA) kit speci¢c for the rat
ADM from Peninsula Laboratories (Belmont, CA).
Brie£y, approximately 0.5 g tissue was homogenized
with 2 ml Tris-HCl (50 mM pH 7.4). After the cen-
trifugation at 16 000Ug for 10 min, the supernatant
was collected. ADM was extracted from the 0.5-ml
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supernatant on C18 columns eluted with 60% aceto-
nitrile in 1% tri£uoroacetic acid. Eluates were evapo-
rated to dryness using a centrifugal concentrator.
Samples were dissolved in the RIA bu¡er (supplied
with the assay kit). Samples were then incubated
with antibody raised against rat ADM at 4‡C for
20 h. ADM labeled with 125I was then added and
further incubated for 24 h at 4‡C. Free and bound
fractions of 125I-ADM were separated by the addi-
tion of a secondary antibody and centrifugation. Ra-
dioactivity of the pellet was then measured with a
gamma counter and tissue levels of ADM were cal-
culated and expressed as pg/mg protein. The assays
were performed in duplicates. The rat ADM assay
does not have any cross reactivity with human
ADM, amylin, or endothelins. Protein concentration
in the supernatant was then determined by using the
Lowry method [21].
2.3. ADM immunohistochemistry and electron
microscopy
In an additional study, sham-operated and septic
animals (n = 4^6 in each group) were anesthetized
with methoxy£urane at 5 or 20 h after CLP or
sham-operation. The heart was ¢xed by the perfusion
of the coronary artery with a ¢xative solution at a
pressure of 95 mmHg. Brie£y, the lower portion of
the thoracic aorta was ligated and the vena cava was
severed immediately following thoracotomy. A 22-
gauge needle was quickly inserted into the aorta
and normal saline was perfused to remove the blood
in cardiac tissue. This was followed by the infusion
of 100 ml of 4% paraformaldehyde and 0.1% gluta-
raldehyde in 0.1 M phosphate bu¡er (pH 7.4) for the
¢xation of the heart. The £uid was perfused into the
coronary artery through its junction on the aortic
arch. As a result, the thoracic aorta was also ¢xed
when the ¢xative solution was perfused into the
heart.
Immediately following the perfusion and ¢xation,
the heart and thoracic aorta were carefully removed
and further ¢xed with 4% paraformaldehyde for 2 h.
After washing overnight with 0.1 M phosphate bu¡er
pH 7.4, the left ventricle was cut into 40-Wm sections
using a vibrotome and the aorta was cut into 1-mm
rings. Pre-embedding immunohistochemistry tech-
nique was performed to reveal ADM immunostain-
ings in the cardiovascular tissues. The tissues were
rinsed with Tris-bu¡ered saline containing 0.2% Tri-
ton X-100 (TBS-TX), followed by incubation with
TBS containing 5% normal goat serum for 1 h.
The tissues were then incubated with rabbit polyclo-
nal antibody against rat ADM (Peninsula Laborato-
ries, Belmont, CA) in TBS-TX containing 1% bovine
serum albumin for 60 h at 4‡C. The ADM antibody
was diluted at a ratio of 1:1500. The tissue was then
rinsed thoroughly with TBS and incubated in 0.6%
H2O2 containing 70% methanol for 30 min. After
washing, the tissues were transferred to an 1:200
dilution solution of biotinylated goat anti-rabbit
IgG antiserum (Vector Laboratories, Burlingame,
CA), incubated for 30 min at room temperature,
and then reacted with an avidin^biotin^peroxidase
complex (Vector Laboratories, Burlingame, CA) for
1.5 h at room temperature. The reaction products
were revealed by placing the tissues into 3,3P-diami-
nobenzidine (DAB, Sigma) solution containing 100
mg DAB, 40 mg NH4Cl, 200 mg L-D-glucose, and
0.4 mg glucose oxidase in 100 ml of 0.15 M Tris
bu¡er for 5 min. Following thorough wash with
Tris bu¡er, the ventricle sections were mounted on
slides and counter stained with hemotoxylin for light
microscopy evaluation. Additional samples were
processed for electron microscopy examination as
previously described by us [22]. The ultrathin section
was examined under a Philips 300 electron micros-
cope. Aorta blocks were cut into l-Wm-thick sections
for light microscopic evaluation before subjecting
to ultrathin sections. The presence of ADM immu-
noreactivity was examined by a microscope and
quanti¢ed according to the grades of ADM immu-
nostainings (0, no stainings of ADM; 1, minimal;
2, mild; 3, moderate; 4, maximal density). For the
negative control, a non-speci¢c rabbit IgG (Vector
Laboratories) was substituted for the primary anti-
body.
2.4. Statistical analysis
The tissue levels of ADM are expressed as
mean þ S.E.M. Unpaired Student’s t-test or Mann^
Whitney Rank Sum test was used for the comparison
between CLP and sham operation at the speci¢c time
point. The di¡erences were considered signi¢cant at a
P value of 9 0.05.
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3. Results
3.1. ADM levels in cardiovascular tissues
As shown in Fig. 1, the levels of ADM in the
ventricle were 2.64 þ 0.20 and 2.53 þ 0.46 pg/mg pro-
tein at 5 and 20 h after sham-operation, respectively.
At 5 and 20 h after CLP, however, ADM levels in-
creased by 66 and 93%, respectively (P6 0.05, Fig.
1). Similarly, the levels of ADM in the aorta in-
creased by 50% at 5 h after CLP and by 51% at 20
h after CLP as compared with the respective sham-
operated animals (P6 0.05, Fig. 2). Cardiac ADM
levels were approximately 30% of aortic ADM levels
in both sham and septic animals (Figs. 1 and 2).
3.2. Immunohistochemistry
Fig. 3A^C illustrate the representative ADM im-
munohistochemical stainings of the left ventricle in
the sham as well as septic animals. ADM stainings
were observed within the cytoplasm of cardiac myo-
cytes and were localized in the peripheral cytoplasm
and perinuclear region (Fig. 3A^C). ADM immuno-
reactivities were more intense in septic rats (Fig.
3B,C) than in the sham-operated animals (Fig. 3A).
However, there appears to be no di¡erence in the
ADM stainings between 5 and 20 h after the onset
of sepsis (Fig. 3B,C). The tissue sections treated with
non-speci¢c rabbit IgG, normal goat serum or TBS
instead of primary antibody (i.e. the negative con-
trol) did not show ADM stainings (Fig. 3D). ADM
immunohistochemical grades in the left ventricles in-
creased by 50 and 43% at 5 and 20 h after CLP,
respectively, as compared with sham-operated ani-
mals (P6 0.05, Fig. 4).
In the thoracic aorta, ADM immunostainings were
only observed in the endothelial cells. There was no
ADM immunoreactivity in the vascular smooth
muscle cells, adventitia or connective tissues in
sham-operated or septic animals (Fig. 5A^C).
Although ADM stainings were clearly observed in
the vascular endothelial cells in the sham-operated
animals (Fig. 5A), the immunoreactivity increased
at 5 h after CLP (Fig. 5B) as well as 20 h after the
onset of sepsis (Fig. 5C). There were no immunore-
action products in the vascular endothelial cells in
the negative control section (Fig. 5D). Because of
the fact that ADM stainings were limited in the vas-
cular endothelial cells, we did not attempt to quanti-
fy the changes during sepsis by the grading system.
3.3. Electron microscopy
The precise localization of ADM immunoreaction
products was examined using immunohistochemistry
and electron microscopy. Fig. 6A shows the ADM
immunostainings in the cardiac muscle cells using
electron microscopy. The ADM immunoreaction
products were found in the sarcoplasm and were
Fig. 1. Changes in cardiac ADM levels at 5 and 20 h after ce-
cal ligation and puncture (CLP) or sham-operation (Sham).
The data are presented as mean þ S.E.M. (n = 5^6/group) and
compared by unpaired Student’s t-test at each point after CLP.
*P6 0.05 versus the respective sham.
Fig. 2. Changes in aortic ADM levels at 5 and 20 h after cecal
ligation and puncture (CLP) or sham-operation (Sham). The
data are presented as mean þ S.E.M. (n = 5^6/group) and com-
pared by unpaired Student’s t-test at each point after CLP.
*P6 0.05 versus the respective sham.
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con¢ned to the cytoplasmic matrix or associated with
the outer membranes of mitochondria and vesicles
(Fig. 6A). There were no immunostainings in the
cardiac myocytes in the negative control sections
(Fig. 6B). Examination of the aortic tissues revealed
that ADM only appeared in the vascular endothelial
cells. As demonstrated in Fig. 7A,B, the dark ADM
immunoreaction products were seen in the cytoplasm
at 20 h after CLP. ADM was in the cytoplasmic
matrix and it was also attached to the membrane
of small vesicles in the endothelial cells (Fig. 7A,B).
The ADM immunoreaction products, however, were
not homogeneously distributed in the endothelial
cells. Immunoprecipitate appeared as patches in
some regions of the cytoplasm (Fig. 7A,B). Immuno-
reaction products were not observed in the vascular
smooth muscle cells, adventitia or connective tissues
(Fig. 7A,B). Negative control showed no immunore-
action products (Fig. 7C).
4. Discussion
A number of studies have demonstrated that
ADM exists not only in the adrenal medulla, but
also in a variety of other organs, such as the heart
Fig. 3. ADM immunohistochemical staining of the left ventricle at 5 and 20 h after cecal ligation and puncture (CLP) or sham-opera-
tion (Sham). ADM immunoreaction products were observed in cytoplasm of ventricular myocytes (A^C). ADM immunostaining in
the left ventricle was increased in septic animals (B,C) compared to sham-operated animals (A). There was no immunoreaction prod-
uct in the negative control section (D). Scale bar: 100 Wm. (A) Sham 20 h. (B) CLP 5 h. (C) CLP 20 h. (D) Negative control.
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and blood vessels [6,10,11,13,23^25]. Although the
direct e¡ect of ADM on myocardial and vascular
contractility has not been well described during sep-
sis, the increased plasma levels of ADM were found
to be associated with cardiovascular responses and
the changes in the pulmonary arterial pressure in
patients with heart failure [14,26,27]. It has been re-
ported that the systemic administration of ADM re-
sulted in an increase in cardiac output and stroke
volume in mammals [8,28]. In the conscious sheep,
infusion of human ADM produced a marginal de-
crease in mean arterial blood pressure and a signi¢-
cant increase in heart rate, whereas total peripheral
conductance was markedly elevated [29]. Plasma lev-
els of ADM during the early and subacute phase of
acute myocardial infarction complicated with heart
failure were signi¢cantly higher than the levels ob-
served in normal subjects [15]. These ¢ndings may
suggest that ADM plays a role in regulating cardio-
vascular responses under various pathophysiological
conditions.
We have previously demonstrated that cardiac
output and organ blood £ow were signi¢cantly in-
creased and peripheral vascular resistance was de-
Fig. 4. Changes in ADM immunohistochemistry staining grades
in the ventricles at 5 and 20 h after cecal ligation and puncture
(CLP) or sham operation (Sham). There are four to six animals
in each group. The data was compared by Rank Sum test at
each time point. *P6 0.05 versus the respective sham.
Fig. 5. ADM immunohistochemical stainings in the thoracic aorta at 5 and 20 h after cecal ligation and puncture (CLP) or sham-op-
eration (Sham). ADM immunoreaction products were observed in aortic endothelial cells (A^C). No immunostainings were seen in
vascular smooth muscle cells, adventitia or connective tissues (A^C). ADM immunostaining in the vascular endothelial cells was in-
creased in septic animals (B,C) compared to sham-operated animals (A). There were no immunoreaction products in the negative con-
trol section (D). Scale bar: 50 Wm. (A) Sham 20 h. (B) CLP 5 h. (C) CLP 20 h. (D) Negative control.
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creased during the early stage of sepsis (i.e. 2^10 h
after CLP) [3]. The factors responsible for the hemo-
dynamic and cardiovascular alterations after the on-
set of sepsis are still not fully understood. Clinical
reports have demonstrated that circulating levels of
ADM are elevated more than 40-fold in patients with
sepsis [16,18]. In comparison with other pathophysio-
logical conditions, plasma concentrations of ADM in
septic patients were markedly higher than that in
patients with renal failure, heart failure or severe
Fig. 6. Ultramicrographs of ADM immunohistochemical stainings in ventricular myocytes at 5 h after CLP (A). ADM immunoreac-
tion products were present in the cytoplasmic matrix (A; arrowhead) or associated with the outer membranes of mitochondria and
vesicles (A; arrows). There was no immunostaining in the negative control sections (B). m, mitochondrion; v, vesicle; mf, myo¢bril.
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hypertension (plasma ADM increased two to four
times under those conditions) [18]. In this regard,
our recent studies have shown that plasma levels of
ADM were signi¢cantly elevated during the early,
hyperdynamic stage of sepsis [4]. ADM and its
gene expression were also signi¢cantly upregulated
under such conditions [4]. Infusion of the synthetic
rat ADM at a dose of 8.5 Wg/kg increased cardiac
output, stroke volume and microvascular blood £ow
in various organs and decreased total peripheral re-
sistance [5]. Moreover, administration of anti-ADM
antibodies prevented the occurrence of hyperdynamic
and hypercardiovascular responses observed during
the early stage of polymicrobial sepsis [5]. These ¢nd-
ings suggest that ADM may be an important medi-
ator which produces the hyperdynamic circulation
following the onset of sepsis [4,5]. Moreover, it ap-
pears that the reduction of the vascular ADM re-
sponsiveness may contribute to the transition from
the hyperdynamic to the hypodynamic stage of sepsis
[30]. Although ADM levels increased signi¢cantly in
the systemic circulation after the onset of sepsis [4], it
remains unknown whether ADM is upregulated in
the cardiovascular tissues during sepsis. To deter-
mine this, we measured ADM levels in the cardio-
vascular tissues and its precise cellular localization
during the early and late stages of sepsis.
Our results indicated that ADM levels in the heart
and thoracic aorta increased at the early, hyperdy-
namic stage of sepsis (i.e. 5 h after CLP) and the
elevated tissue levels of ADM persisted at the late,
hypodynamic stage (20 h after CLP). The increased
ADM levels in the cardiovascular tissues were corre-
lated with the upregulated plasma levels of ADM
and its gene expression during sepsis [4]. In our re-
cent study [4], we reported that plasma levels of
ADM increased by 125% (from 85.8 þ 14.1 to
193.4 þ 14.4 pg/ml) at 5 h after CLP. Although it
Fig. 7. Ultramicrographs of ADM immunohistochemical stain-
ings in the thoracic aorta at 20 h after CLP (A,B). Immuno-
staining could be seen in aortic endothelial cells and localized
in the cytoplasmic matrix or associated with membrane of small
vesicles (A,B; arrows). There was no immunoreactivity in the
vascular smooth muscle and adventitia. The negative control
showed no immunoreaction products (C). lu, lumen; el, elastic
lamina.
6
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has been reported that plasma ADM levels increased
by more than 40-fold in septic patients [16,18], the
increase of this peptide in the rat model of sepsis is
relatively moderate. Thus, the increase in ADM lev-
els in the cardiovascular tissue (by 50^93%) is com-
parable to that observed in the circulation [4]. It
should be noted that tissues other than those of the
cardiovascular system may also contribute to the in-
creased level of circulating ADM following the onset
of sepsis. Moreover, we have recently reported that
ADM mRNA in the left ventricle, as determined by
reverse transcription-polymerase chain reaction (RT-
PCR), increased at 2 h after CLP and further in-
creased at 10^20 h after the onset of sepsis [4]. While
ADM gene expression in the thoracic aorta at 2 h
after CLP was similar to sham-operated animals, it
increased at 10 and 20 h after CLP [4]. Thus, ADM
gene expression in cardiovascular system is upregu-
lated following the onset of sepsis. It is likely that the
increased tissue level of ADM is due to the de novo
synthesis of this peptide. It is, however, also possible
that the deposition of circulating ADM in the cardi-
ovascular tissue may have increased during sepsis
since circulating levels of this peptide have been re-
ported to be signi¢cantly increased.
The present study has also indicated that ADM
immunoreaction products were localized in the car-
diac muscle cells of the rat heart. ADM immuno-
reactivity was increased in septic animals, which fur-
ther con¢rms the elevation of ADM levels in the
heart. Under a light microscope, the localization of
ADM in rat heart was the same as that reported in
the human and dog by Jougasaki et al. [13,24].
Although ADM immunohistochemistry ¢ndings in
cardiovascular tissues have been reported at the light
microscopy level [13,24], the precise localization of
ADM in such tissues at the ultrastructural level re-
mains unknown. In this regard, our study shows that
ADM was localized in the cytoplasmic matrix or
associated with the outer membranes of mitochon-
dria and vesicles of the cardiac myocytes. Although
ADM exists in aortic tissues in several species of
animals [24,31], the localization of ADM in the aorta
remains controversial. Jougasaki et al. demonstrated
ADM immunohistochemistry staining in the dog
aorta [24]. They reported that ADM immunostain-
ings were localized in the vascular smooth muscle
cells and that there was no immunoreactivity in the
endothelium, adventitia, or connective tissue [24].
Other studies have indicated that human vascular
endothelial cells produce ADM [32]. ADM gene
transcription increased in cultured endothelial cells
and vascular smooth muscle cells following the ad-
ministration of endotoxin [33]. Our present study
showed that ADM was only present in the vascular
endothelial cells. There was no ADM immunoreac-
tivity in the vascular smooth muscle and adventitia.
The di¡erent results between our study and others
appear to be due to the di¡erent degree of gene tran-
scription for ADM in di¡erent sites of tissues as well
as species di¡erences.
It has been reported that the mechanism responsi-
ble for vascular relaxation by ADM is through the
ADM receptors on the vascular smooth muscle,
which increase cellular cAMP levels, producing the
relaxation of the vascular smooth muscles [34^36].
Speci¢c ADM receptors have also been reported to
be present in the endothelial cells [7,32]. The in-
creased ADM levels in the aorta at 5 h after CLP
is likely associated with the increased binding ca-
pacity of ADM in the aortic tissues. In the late,
hypodynamic stage of sepsis, cardiac output was de-
creased and peripheral vascular resistance increased
[37]. It is possible that the reduced ADM responsive-
ness or other mediators/factors are responsible for
the transition from the early, hyperdynamic to the
late, hypodynamic phase of sepsis. Although the pre-
cise mechanism responsible for producing such tran-
sition remains unknown, our recent studies [30] have
indicated that ADM-induced vascular relaxation de-
creased signi¢cantly in the aorta as well as in intes-
tinal arterioles at 20 h after CLP (i.e. the late, hypo-
dynamic phase of sepsis). In contrast, ADM-induced
vascular relaxation remained unaltered during the
early, hyperdynamic phase. This would suggest
that, despite the increased ADM levels during the
late stage of sepsis, the reduced vascular ADM re-
sponsiveness may be responsible for the transition
from the hyperdynamic phase to the hypodynamic
phase of sepsis. Future studies are required to deter-
mine whether the reduced ADM responsiveness is
due to downregulation of ADM receptors and/or
its signal transduction mechanisms.
In summary, ADM levels in the heart and thoracic
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aorta increased signi¢cantly at 5 h after the onset of
sepsis and remained elevated at 20 h after CLP. Im-
munohistochemistry examination showed that the
ADM immunoreaction products were localized in
the cytoplasm of myocardial cells and aortic endo-
thelial cells. Using electron microscopy, ADM immu-
noreaction products were found in the cytoplasmic
matrixes or associated with the outer membranes of
mitochondria and vesicles in myocytes as well as
aortic endothelial cells. To the best of our knowl-
edge, this is the ¢rst report which shows the ultra-
structural localization of ADM immunostainings in
the cardiovascular tissue under septic conditions. The
present study also suggests that the cardiovascular
tissues, among other organs, may contribute to the
increased levels of plasma ADM under those con-
ditions. Because ADM is localized in myocytes in
the heart and in endothelial cells in the large blood
vessels, this peptide appears to play a di¡erential
role in regulating cardiac and vascular functions
during sepsis as an autocrine and/or paracrine medi-
ator.
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